Detalhe da pesquisa
1.
Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience - A Multicenter Retrospective Study.
Oncology
; 100(12): 666-673, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36044833
2.
Inequalities in cancer screening, prevention and service engagement between UK ethnic minority groups.
Br J Nurs
; 31(10): S14-S24, 2022 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35648663
3.
BCL2 inhibition: back to the future!
Blood
; 143(18): 1787-1788, 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38696193
4.
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
Blood
; 133(26): 2765-2775, 2019 06 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30862645
5.
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.
Br J Haematol
; 188(6): 918-923, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31682002
6.
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
Blood
; 127(4): 411-9, 2016 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26542378
7.
Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.
Br J Haematol
; 178(3): 364-379, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28449207
8.
New Agents to Treat Chronic Lymphocytic Leukemia.
N Engl J Med
; 374(22): 2185-6, 2016 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27248633
9.
Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059.
Blood
; 129(20): 2808-2810, 2017 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-28377400
10.
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.
Haematologica
; 104(2): e68-e71, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30190341
11.
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.
Clin Cancer Res
; 29(2): 331-340, 2023 01 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36378548
12.
Centralised RECIST Assessment and Clinical Outcomes with Lenvatinib Monotherapy in Recurrent and Metastatic Adenoid Cystic Carcinoma.
Cancers (Basel)
; 13(17)2021 Aug 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34503145
13.
Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.
Clin Cancer Res
; 26(12): 2810-2818, 2020 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32156743
14.
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents.
Blood Adv
; 4(16): 3977-3989, 2020 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32841336
15.
Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines.
Cancers (Basel)
; 10(4)2018 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29690649
16.
BTK mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib.
Blood Adv
; 7(14): 3378-3381, 2023 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37257190
17.
Chronic lymphocytic leukaemia therapy: is less more?
Lancet Haematol
; 9(3): e169-e171, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35240069
18.
Successful Retreatment With Venetoclax in a Patient With Chronic Lymphocytic Leukemia.
Hemasphere
; 6(8): e752, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35935612
19.
Limitations of Monitoring Disease Progression Using Circulating Tumor DNA in Lymphoma: An Example From Primary Cutaneous DLBCL Leg-type.
Hemasphere
; 6(3): e690, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35261967
20.
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.
Blood Adv
; 6(15): 4553-4557, 2022 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35736670